PCML
RPRX icon

Pavaki Capital Management LLC’s Royalty Pharma RPRX Stock Holding History

Pavaki Capital Management LLC’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.47M Hold
44,000
– – 0.86% 25
2026
Q1 		$2.11M Hold
44,000
– – 0.9% 24
2025
Q4 		$1.7M Buy
+44,000
New +$1.68M 0.67% 30

Other funds holding RPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Mitsubishi UFJ Trust & Banking
Mitsubishi UFJ Trust & Banking Tokyo, Japan $45.7B AUM 34.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Pavaki Capital Management LLC's RPRX Position: Q2 2026 in Review

Pavaki Capital Management LLC held its Royalty Pharma (RPRX) position steady in Q2 2026 at 44,000 shares worth $2.47M. The position accounts for 0.86% of the portfolio, ranked #25.

Pavaki Capital Management LLC first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. 296 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Pavaki Capital Management LLC held 44,000 shares of Royalty Pharma worth $2.47M as of Q2 2026.
  • Pavaki Capital Management LLC left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.86% of Pavaki Capital Management LLC's portfolio in Q2 2026, its #25 holding.
  • Pavaki Capital Management LLC first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • 296 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Pavaki Capital Management LLC's 13F filing for Q2 2026, filed 7 Aug 2026.